Ratcliff 2007 IDN.

Methods	Trial design: An open‐label RCT Follow‐up: A symptom questionnaire, physical examination, malaria film and Hb measurement daily until fever and parasites cleared then weekly to day 42 Adverse event monitoring: A symptom questionnaire at each visit
Participants	Number of participants: 774 Inclusion criteria: Weight > 10 kg, fever or a history of fever in the preceding 48 hrs, slide confirmed malaria (P. falciparum, P. vivax or mixed infections) Exclusion criteria: Pregnancy or lactation, danger signs or signs of severity, parasitaemia > 4%, concomitant disease requiring hospital admission
Interventions	1. DHA‐P, fixed dose combination, 40 mg/320 mg tablets (Artekin: Holleykin) Total dose: DHA 6.75 mg/kg + P 54 mg/kg in 3 divided doses, given once daily for 3 days 2. Artemether‐lumefantrine, fixed dose combination, 20 mg/120 mg tablets (Coartem: Novartis) 10 to 15 kg 1 tablet twice daily for 3 days 15 to 25 kg 2 tablets twice daily for 3 days 25 to 35 kg 3 tablets twice daily for 3 days > 35 kg 4 tablets twice daily for 3 days Only the first dose of each day was supervised. All participants advised to take each dose with a biscuit or milk.
Outcomes	Parasitological failure at days 42 and 28, PCR‐adjusted and PCR‐unadjusted P. vivax during follow‐up Gametocyte carriage after treatment Anaemia during follow‐up Adverse events Not included in the review: Fever clearance Parasite clearance
Notes	Country: Indonesia Setting: Rural outpatient clinics Transmission: Unstable Resistance: Multiple‐drug resistance Dates: Jul 2004 to Jun 2005 Funding: Wellcome Trust UK and National Health and Medical Research Council Australia
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"A randomisation list was generated in blocks of 20 patients by an independent statistician".
Allocation concealment (selection bias)	Low risk	"With each treatment allocation concealed in an opaque sealed envelope". No further details given.
Blinding for microscopy outcomes (performance bias and detection bias)	Low risk	The microscopists were blinded to treatment allocation.
Blinding for adverse events (performance and detection bias)	High risk	An open label trial.
Incomplete outcome data (attrition bias) All outcomes	High risk	The primary outcome data are unpublished data including only participants with P. falciparum mono or co‐infection at baseline. Losses to follow‐up were high in both groups at day 42 (28.4 % DHA‐P versus 25.6 % AL6) and moderate at day 28 (19% DHA‐P versus 17.6% AL6).
Selective reporting (reporting bias)	Low risk	All WHO outcomes reported. Day 42 outcomes may underestimate failure with DHA‐P due to its long half‐life.
Other bias	Low risk	No other sources of bias identified.